MONMOUTH JUNCTION, N.J., June 26 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company focused on the development of innovative, inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, today announced the appointment of Nicholas Gurreri as Senior Vice President, Commercial Operations and Business Development.
Mr. Gurreri brings twenty years of global and US commercial pharmaceutical and medical device experience to Transave. He has held various management positions at Bristol-Myers Squibb Company (BMS), Pharmacia Corp. and Pfizer, Inc. In his most recent role as the head of Pfizer’s Global Anti-infective Therapeutic Area, Mr. Gurreri was responsible for managing Zyvox(R) and Vfend(R), which had combined annual sales of over $1 billion, commercializing pipeline products and working closely with R&D leadership to formulate discovery and licensing strategies. Earlier at Pharmacia and then at Pfizer, Mr. Gurreri was responsible for the development of the ophthalmology therapeutic area strategy and led the team that developed the first billion dollar ophthalmic brand, Xalatan(R). Mr. Gurreri began his pharmaceutical career at BMS, where he held positions of increasing responsibility in the cardiovascular marketing area, ultimately leading BMS’ largest US brands, Pravachol(R) and Capoten(R). In his last role at BMS, Mr. Gurreri had global franchise responsibility for a portfolio of wound care products in the Convatec medical device division.
“Nick joins Transave at an exciting time as we begin Phase II studies with our lead compound, Arikace(TM) (liposomal amikacin for inhalation), for the management of lung infections in cystic fibrosis patients,” said CEO Tim Whitten. “With Nick’s appointment, our company’s new executive management team is now complete. Given his terrific combination of commercial leadership and strategic marketing skills, Nick will no doubt prove to be a major contributor to the development of our compounds to address the unmet needs in the market and the expansion of our pipeline of inhaled anti-infective programs.”
Mr. Gurreri earned a Master of Business Administration from the Tepper School of Business at Carnegie Mellon University and a Bachelor of Science degree from The University of Delaware.
About Transave, Inc.
Transave is a privately-held biotechnology company whose mission is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products. Transave’s product candidates are delivered via inhalation directly to the site of the disease. The company’s proprietary liposomal delivery technology provides for prolonged release of a drug in the lung while minimizing systemic exposure, which may improve the therapeutic index of commonly used pharmaceutical products.
Transave has two products in clinical development: Liposomal Amikacin for Inhalation (Arikace(TM)) for Pseudomonas aeruginosa infections in cystic fibrosis patients and Cisplatin Lipid Complex for cancers that affect the lung. For more information about Transave’s technology and development programs, visit http://www.transaveinc.com/.
Zyvox(R), Vfend(R), and Xalatan(R) are registered trademarks of Pfizer Inc. Pravachol(R) and Capoten(R) are registered trademarks of Bristol-Myers Squibb Company.
Arikace(TM) is a trademark of Transave, Inc.
Transave, Inc.
CONTACT: Joann Sauchelli of Transave, Inc., +1-732-438-9434,jsauchelli@transaveinc.com
Web site: http://www.transaveinc.com/
